Brookline Capital Downgrades Caribou Biosciences to Hold

Benzinga Newsdesk www.benzinga.com Negative 88.9%

Neg 88.9% Neu 0% Pos 0%

Brookline Capital analyst Leah Cann downgrades Caribou Biosciences (NASDAQ:CRBU) from Buy to Hold.

Comments

No comments yet. Be the first!